<DOC>
	<DOC>NCT01937299</DOC>
	<brief_summary>The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy (TRAVATAN Z®).</brief_summary>
	<brief_title>Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®</brief_title>
	<detailed_description>This study was divided into 2 sequential phases. The Screening/Eligibility Phase included one Screening Visit and two Eligibility Visits, during which subjects washed out of all other intraocular pressure (IOP)-lowering medications and dosed with TRAVATAN Z®, 1 drop instilled in each eye once daily for 28 days. Subjects who met all inclusion/exclusion criteria were randomized at the second Eligibility Visit. The Treatment Phase consisted of two on-therapy visits (Week 2 and Week 6).</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis of open angle glaucoma or ocular hypertension; Mean IOP measurements in at least 1 eye (study eye) of ≥ 21 mmHg and &lt;32 mmHg at 8 AM while on travoprost monotherapy at 2 consecutive visits (Eligibility 1 and Eligibility 2); Able to understand and sign Informed Consent form; Other protocoldefined inclusion criteria may apply. Women of childbearing potential who are pregnant, breastfeeding, or do not agree to use an adequate birth control method throughout the study; Any form of glaucoma other than open angle glaucoma or ocular hypertension; Severe central visual field loss; Chronic, recurrent, or severe inflammatory eye disease; Ocular trauma within the past 6 months; Ocular infection or ocular inflammation within the past 3 months; Bestcorrected visual acuity score worse than approximately 20/80 Snellen; Eye surgery within the past 6 months; Any condition, including severe illness, which would make the subject unsuitable for the study in the opinion of the Investigator; Use of any additional topical or systemic ocular hypertensive medication during the study; Patients who, in the opinion of the Investigator, cannot discontinue all IOPlowering ocular medication(s) per the appropriate washout schedule prior to Eligibility 1 Visit; Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>prostaglandin analogue</keyword>
	<keyword>brinzolamide</keyword>
	<keyword>brimonidine</keyword>
</DOC>